Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 131 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Active Breast Cancer Treatment Clear all
Completed Phase 1 Interventional

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

NCT00508586
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Involving Family to Improve Communication in Breast Cancer Care

NCT03283553
View directory record Official record
Conditions
Active Breast Cancer Treatment
Interventions
Checklist, MyChart, OpenNotes, Usual Care
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

NCT02124902
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

NCT03149549
View directory record Official record
Conditions
Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer
Interventions
CX-2009
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 4, 2026, 10:27 PM EDT
Recruiting No phase listed Observational

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

NCT07023887
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
6-12-25 Training Regimen, 8x8 Training Regimen, 5/5/5 Cluster Set Training Regimen, Double Training Regimen
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Not applicable Interventional

Heading Off Peripheral Neuropathy With Exercise

NCT00869804
View directory record Official record
Conditions
Peripheral Nervous System Disorders, Breast Neoplasms, Chemotherapy
Interventions
Aerobic/ Resistance Exercise Intervention, Attention control
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 4, 2026, 10:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NCT05573555
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Yoga for Breast Cancer

NCT01985945
View directory record Official record
Conditions
Women With Stage I or II Breast Cancer Undergoing Active Radiation Therapy
Interventions
Yoga
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 4, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 4, 2026, 10:27 PM EDT
Not listed Not applicable Interventional

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

NCT01157130
View directory record Official record
Conditions
Early Stage Breast Cancer (Stage 0-III)
Interventions
Exercise Regimen
Other
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

NCT03773133
View directory record Official record
Conditions
Small Cell Lung Cancer and Breast Cancer
Interventions
Satoreotide tetraxetan, Satoreotide trizoxetan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy

NCT01900418
View directory record Official record
Conditions
Joint Pain, Breast Cancer
Interventions
Walk with Ease
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 4, 2026, 10:27 PM EDT
Not listed Not applicable Interventional

Behavioral Weight Loss and Exercise After Treatment (BEAT)

NCT02052115
View directory record Official record
Conditions
Breast Cancer
Interventions
12 month exercise and weight loss intervention
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 4, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer

NCT04449809
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
30 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

NCT00529984
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer
Interventions
AVX701
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 4, 2026, 10:27 PM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Not applicable Interventional

A Research Study for Latina Women After Breast Cancer Treatment

NCT03645005
View directory record Official record
Conditions
Cancer-related Problem/Condition, Quality of Life, Stress, Emotional
Interventions
"My Guide" (psychoeducation & self-management program), "My Health" (health education program)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

NCT00070057
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

NCT03523195
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Cancer Survivor, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sedentary Lifestyle
Interventions
Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Questionnaire Administration, Physical Performance Testing
Behavioral · Other · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 4, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

NCT02627274
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Cancer of Head and Neck
Interventions
RO6874281, Trastuzumab, Cetuximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 4, 2026, 10:27 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

NCT05079360
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 4, 2026, 10:27 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT07214662
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0587, Giredestrant, Omeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 10:27 PM EDT